{
    "clinical_study": {
        "@rank": "75746", 
        "brief_summary": {
            "textblock": "To evaluate an HIV synthetic lipopeptide candidate vaccine component, P3C541b, at two dose\n      levels, administered subcutaneously (s.c.) in a randomized, double-blind, placebo controlled\n      study."
        }, 
        "brief_title": "A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The prospective volunteers will be screened and HLA typed for Class I MHC haplotypes. Only\n      volunteers possessing HLA alleles A33, B8, B27, B35 or Bw62 or any combination thereof will\n      be enrolled in the study. Subjects will be allocated to 1 of 2 study groups. Group 1 will\n      receive 70 mcg of P3C541b or the placebo and Group II will receive 350 mcg of P3C541b or the\n      placebo. NOTE: Enrollment for Group II wil not begin until at least 5 Group I participants\n      have reached day 14 without serious adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have or be:\n\n          -  Healthy\n\n          -  Negative ELISA for HIV.\n\n          -  One or more HLA alleles:\n\n          -  A33, B8, B27, B35, or Bw62.\n\n          -  Negative for Hepatitis B surface antigen.\n\n          -  Normal urine dipstick.\n\n          -  Normal history and physical examination.\n\n          -  Availability for follow-up planned duration of the study (12 months).\n\n          -  Viable EBV line prior to enrollment.\n\n        Risk behavior: Required:\n\n          -  Lower risk sexual behavior as defined by AVEG.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with any of the following symptoms or conditions are excluded:\n\n          -  Medical or psychiatric condition or occupational responsibilities, which preclude\n             subject compliance with the protocol (e.g., recent suicidal ideation or present\n             psychosis).\n\n          -  Active syphilis. NOTE: If the serology is documented to be false positive due to a\n             remote (> 6 months) treated infection, the volunteer is eligible.\n\n          -  Hepatitis B surface antigenemia.\n\n          -  Active tuberculosis. NOTE: Volunteers with a positive PPD and a normal chest X-Ray\n             showing no evidence of TB and not requiring INH therapy are eligible.\n\n        Patients with any of the following prior conditions are excluded:\n\n          -  History of immunodeficiency, chronic illness, malignancy, autoimmune disease.\n\n          -  History of cancer, unless there has been surgical excision followed by a sufficient\n             observation period to give a reasonable assurance of a cure.\n\n          -  History of anaphylaxis or history of other serious adverse reactions to vaccines.\n\n          -  History of serious allergic reaction to any substance, requiring hospitalization or\n             emergent medical care.\n\n          -  History of suicide attempts or past psychosis.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  History of use of immunosuppressive medication.\n\n          -  Live attenuated vaccines within 60 days of study.\n\n        NOTE:\n\n          -  Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are\n             not exclusionary but should be given at least 2 weeks away from HIV immunizations.\n\n          -  Use of experimental agents within 30 days prior to study.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Receipt of blood products or immunoglobulin in the past 6 months.\n\n        Risk Behavior:\n\n        Excluded:\n\n          -  Subjects with identifiable higher risk behavior for HIV infection as determined by\n             screening questionnaire designed to identify risk factors for HIV infection.\n\n          -  History of injection drug use within the last 12 months prior to enrollment.\n\n          -  Higher or intermediate risk sexual behavior as defined by AVEG."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000845", 
            "org_study_id": "AVEG 021"
        }, 
        "intervention": {
            "intervention_name": "P3C541b Lipopeptide", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Vaccines, Synthetic", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "212051901"
                    }, 
                    "name": "Johns Hopkins Univ / School of Hygiene & Public Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt Univ Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98144"
                    }, 
                    "name": "Univ of Washington / Pacific Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects", 
        "overall_official": {
            "last_name": "Schwartz D", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000845"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2002"
    }, 
    "geocoordinates": {
        "Johns Hopkins Univ / School of Hygiene & Public Health": "39.29 -76.612", 
        "Univ of Washington / Pacific Med Ctr": "47.606 -122.332", 
        "Vanderbilt Univ Hosp": "36.166 -86.784"
    }
}